Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy

In the present era of entecavir (ETV) use for chronic hepatitis B (CHB), the prognostic factors in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remain unclear. The aims of the present study were to investigate the prognostic factors in patients with HBV-related HCC treated with ETV...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2013-11, Vol.6 (5), p.1213-1218
Main Authors: NISHIKAWA, HIROKI, NISHIJIMA, NORIHIRO, ARIMOTO, AKIRA, INUZUKA, TADASHI, KITA, RYUICHI, KIMURA, TORU, OSAKI, YUKIO
Format: Article
Language:English
Subjects:
Antigens
Body mass index
Cancer therapies
Clinical outcomes
Clinical trials
Confidence intervals
Deoxyribonucleic acid
Diabetes
DNA
entecavir
Enzymes
Females
Hepatitis
Hepatitis B
hepatitis B virus
hepatocellular carcinoma
Liver cancer
Liver cirrhosis
Medical imaging
Medical prognosis
Mortality
Multivariate analysis
NMR
Nuclear magnetic resonance
Oncology
Patients
Phosphatase
prognostic factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the present era of entecavir (ETV) use for chronic hepatitis B (CHB), the prognostic factors in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remain unclear. The aims of the present study were to investigate the prognostic factors in patients with HBV-related HCC treated with ETV who underwent curative therapy. A total of 74 HBV-related HCC patients treated with ETV who underwent curative therapy were analyzed. Predictive factors associated with overall survival (OS) and recurrence-free survival (RFS) were examined using univariate and multivariate analysis. Our study population included 49 males and 25 females with a median age of 62 years. The median observation period was 3.4 years (range, 0.2-11.5 years). The 1-, 3- and 5-year cumulative OS rates were 100, 89.8 and 89.8%, respectively. The corresponding RFS rates were 82.8, 52.1 and 25.6%, respectively. In this study, 73 patients (98.6%) achieved an HBV DNA level of
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2013.1578